Last reviewed · How we verify
NSAIDs
At a glance
| Generic name | NSAIDs |
|---|---|
| Also known as | Ibuprofen, diclofenac, Voltaren, 2- Second group: will receive systemic nonsteroidal anti-inflammatory drugs in the analgesic and anti-inflammatory dosage and paracetamol. |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Families With Twins or Siblings Discordant for Rheumatic Disorders
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis (NA)
- Hip Arthroscopy Versus Conservative Treatment for Borderline Hip Dysplasia (NA)
- Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis (PHASE4)
- Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older
- The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster (NA)
- Ear Pressure Points Plus Pain Meds for Faster Kidney Stone Pain Relief (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NSAIDs CI brief — competitive landscape report
- NSAIDs updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI